Latest news with #NexoBrid
Globe and Mail
12-03-2025
- Health
- Globe and Mail
Burn Pain Market to Reach New Heights in Growth by 2034, DelveInsight Predicts
The Key Burn Pain Companies in the market include - Medical Developments International, Cumberland Pharmaceuticals, Janssen Research & Development, Cephalon, and others. DelveInsight's 'Burn Pain Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Burn Pain, historical and forecasted epidemiology as well as the Burn Pain market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Some of the key facts of the Burn Pain Market Report: The Burn Pain market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In August 2024, MediWound Ltd. (Nasdaq: MDWD), a global leader in enzymatic therapeutics for tissue repair, announced that the U.S. Food and Drug Administration (FDA) has approved NexoBrid® (anacaulase-bcdb) for eschar removal in pediatric patients from newborns to 18 years old with deep partial- and full-thickness thermal burns. This approval expands NexoBrid's authorization for all age groups in the U.S., aligning with its approvals in the European Union and Japan. In 2023, the US maintained the largest market share among the 7MM, reaching USD 140 million. Projections indicate that this trend will persist, with the US expected to further strengthen its market dominance and remain the leading player by 2034. In 2023, Germany and the UK in the EU4 and the UK both achieved market shares exceeding USD 20 million, with France following closely behind. In contrast, Italy had the smallest market share among these regions during the same period. Opioid analgesics dominated the current treatment market for both inpatient and outpatient care, with an estimated market value of approximately USD 130 million in 2023. In 2023, the US recorded over 2 million incident cases of burns, with numbers expected to rise by 2034. In 2023, approximately 0.4 million treated incident burn cases requiring pain management therapies were reported in the US, with expectations for change during the study period from 2020 to 2034. The gender distribution indicates a male dominance across the 7MM, with around 0.29 million male cases and 0.26 million female cases reported in the US in 2023. Key Burn Pain Companies: Medical Developments International, Cumberland Pharmaceuticals, Janssen Research & Development, Cephalon, and others Key Burn Pain Therapies: Methoxyflurane (PENTHROX), Caldolor, JNJ-42160443, ACTIQ, and others The Burn Pain epidemiology based on etiology-specific cases analyzed that Etiology Specific Incident Cases of Burns is classified into Flame, Contact, Scald, Electrical, Chemical, and Others The Burn Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Burn Pain pipeline products will significantly revolutionize the Burn Pain market dynamics. Burn Pain Overview An organic tissue injury known as a burn is mostly brought on by heat, radiation, radioactivity, electricity, friction, or chemical contact. Get a Free sample for the Burn Pain Market Report - Burn Pain Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Burn Pain Epidemiology Segmentation: The Burn Pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalence of Burn Pain Prevalent Cases of Burn Pain by severity Gender-specific Prevalence of Burn Pain Diagnosed Cases of Episodic and Chronic Burn Pain Download the report to understand which factors are driving Burn Pain epidemiology trends @ Burn Pain Epidemiology Forecast Burn Pain Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Burn Pain market or expected to get launched during the study period. The analysis covers Burn Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Burn Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Burn Pain Therapies and Key Companies Burn Pain Market Strengths The increasing incidence of patients with burns is expected to propel the treatment market in the future, adding opportunities for new pharma players Burn Pain Market Opportunities The rising incidence of burn pain indicates increasing pharmacological treatment demands, thereby crafting lucrative opportunities for new pharma players Scope of the Burn Pain Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Burn Pain Companies: Medical Developments International, Cumberland Pharmaceuticals, Janssen Research & Development, Cephalon, and others Key Burn Pain Therapies: Methoxyflurane (PENTHROX), Caldolor, JNJ-42160443, ACTIQ, and others Burn Pain Therapeutic Assessment: Burn Pain current marketed and Burn Pain emerging therapies Burn Pain Market Dynamics: Burn Pain market drivers and Burn Pain market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Burn Pain Unmet Needs, KOL's views, Analyst's views, Burn Pain Market Access and Reimbursement Table of Contents 1. Burn Pain Market Report Introduction 2. Executive Summary for Burn Pain 3. SWOT analysis of Burn Pain 4. Burn Pain Patient Share (%) Overview at a Glance 5. Burn Pain Market Overview at a Glance 6. Burn Pain Disease Background and Overview 7. Burn Pain Epidemiology and Patient Population 8. Country-Specific Patient Population of Burn Pain 9. Burn Pain Current Treatment and Medical Practices 10. Burn Pain Unmet Needs 11. Burn Pain Emerging Therapies 12. Burn Pain Market Outlook 13. Country-Wise Burn Pain Market Analysis (2020–2034) 14. Burn Pain Market Access and Reimbursement of Therapies 15. Burn Pain Market Drivers 16. Burn Pain Market Barriers 17. Burn Pain Appendix 18. Burn Pain Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
12-03-2025
- Health
- Globe and Mail
Skin Burns Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Drugs Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight
Skin Burns companies are Smith+Nephew, Mölnlycke Health Care AB, Convatec Inc., 3M, Coloplast Group, Medtronic, Accell Group, Anika Therapeutics, Inc., B. Braun Melsungen AG, Cardinal Health, DeRoyal Industries, Hollister, Integra LifeSciences Corporation, Medline Industries, Inc., PAUL HARTMANN AG, Essity Aktiebolag, Avita Medical, Suwelack Skin and Health Care AG, Healthpoint, Fort Worth, Advanced BioHealing, Mallinckrodt, RenovaCare, among others. (Albany, USA) DelveInsight's " Skin Burns Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Skin Burns, historical and forecasted epidemiology as well as the Skin Burns market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Skin Burns market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Skin Burns market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Skin Burns treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Skin Burns market. Some facts of the Skin Burns Market Report are: According to DelveInsight, Skin Burns market size is expected to grow at a decent CAGR by 2034. Leading Skin Burns companies working in the market are Smith+Nephew, Mölnlycke Health Care AB, Convatec Inc., 3M, Coloplast Group, Medtronic, Accell Group, Anika Therapeutics, Inc., B. Braun Melsungen AG, Cardinal Health, DeRoyal Industries, Hollister, Integra LifeSciences Corporation, Medline Industries, Inc., PAUL HARTMANN AG, Essity Aktiebolag, Avita Medical, Suwelack Skin and Health Care AG, Healthpoint, Fort Worth, Advanced BioHealing, Mallinckrodt, RenovaCare, among others. Key Skin Burns Therapies expected to launch in the market are NexoBrid/KMW-1, Kerecis Omega3, StrataGraft, MW-III, DenovoSkin (EHSG-KF), and many others. In August 2024, Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for NexoBrid® (anacaulase-bcdb) for eschar removal in pediatric patients with deep partial-thickness and/or full-thickness thermal burns. In May 2024, AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for the RECELL GO™ System, its next-generation autologous cell harvesting device that harnesses the regenerative properties of a patient's own skin to treat thermal burn wounds and full-thickness skin defects. Skin Burns Overview Skin burns are tissue injuries caused by heat, chemicals, electricity, radiation, or friction, leading to cell damage, inflammation, and potential complications. Burns are classified into three main degrees based on severity: First-degree burns affect only the epidermis, causing redness, pain, and mild swelling (e.g., sunburns). Second-degree burns extend into the dermis, resulting in blisters, intense pain, and risk of infection. Third-degree burns damage all skin layers, potentially affecting nerves, muscles, and bones, leading to numbness, scarring, and permanent tissue loss. Burns can be thermal (fire, hot liquids, steam), chemical (acids, alkalis), electrical (high-voltage exposure), or radiation-induced (UV exposure, radiation therapy). The severity depends on burn depth, percentage of total body surface area (TBSA) affected, and location. Skin burns Treatment varies based on burn severity. Minor burns require cooling, wound care, pain management, and topical antibiotics, while severe burns necessitate hospitalization, intravenous fluids, infection control, debridement, skin grafts, and reconstructive surgery. Advanced therapies, including stem cell treatments, bioengineered skin substitutes, and regenerative medicine, are improving recovery outcomes. Early intervention, proper wound management, and multidisciplinary care are essential in minimizing scarring, functional impairment, and long-term complications in burn patients. Do you know what will be the Skin Burns market share in 7MM by 2034 @ Skin Burns Treatment Market Skin Burns Market The Skin Burns market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Skin Burns market trends by analyzing the impact of current Skin Burns therapies on the market and unmet needs, and drivers, barriers, and demand for better technology. This segment gives a thorough detail of the Skin Burns market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Skin Burns market data are presented with relevant tables and graphs to give a clear view of the market at first sight. The skin burns market is driven by rising burn injuries globally, advancements in wound care technologies, and increasing awareness of specialized burn treatments. The growing incidence of thermal, chemical, and electrical burns, particularly in industrial settings, household accidents, and conflict zones, is fueling demand for advanced burn care products. Innovations in bioengineered skin substitutes, stem cell therapy, and regenerative medicine have significantly improved burn healing and scar reduction. Additionally, government initiatives, improved healthcare infrastructure, and reimbursement policies are supporting market expansion. The increasing use of hydrocolloid dressings, antimicrobial wound care, and skin grafting procedures is further enhancing patient outcomes. However, the market faces barriers such as high treatment costs, limited access to advanced therapies in developing regions, and the risk of infections and complications. Severe burns require specialized treatment centers, which are not always available, leading to delayed or inadequate care. Additionally, stringent regulatory approvals for new burn treatments, variability in insurance coverage, and challenges in developing cost-effective solutions hinder market growth. Despite these challenges, ongoing research into novel wound healing technologies, autologous cell-based therapies, and nanotechnology-based dressings is expected to drive innovation and improve the future landscape of the skin burns treatment market. According to DelveInsight, the Skin Burns market in 7MM is expected to witness a major change in the study period 2020-2034. Skin Burns Epidemiology The Skin Burns epidemiology section provides insights into the historical and current Skin Burns patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Skin Burns market report also provides the diagnosed patient pool, trends, and assumptions. Interested to know how the emerging diagnostic approaches will be contributing in increased Skin Burns diagnosed prevalence pool? Download report @ Skin Burns Epidemiology Forecast Skin Burns Drugs Uptake This section focuses on the uptake rate of the potential Skin Burns drugs recently launched in the Skin Burns market or expected to be launched in 2020-2034. The analysis covers the Skin Burns market uptake by drugs, patient uptake by therapies, and sales of each drug. Skin Burns Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Skin Burns market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Skin Burns Pipeline Development Activities The Skin Burns report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Skin Burns key players involved in developing targeted therapeutics. Download report to know which TOP 3 therapies will be capturing the largest Skin Burns market share by 2034? Click here @ Skin Burns Medication and Companies Skin Burns Therapeutics Assessment Major key companies are working proactively in the Skin Burns Therapeutics market to develop novel therapies which will drive the Skin Burns treatment markets in the upcoming years are Smith+Nephew, Mölnlycke Health Care AB, Convatec Inc., 3M, Coloplast Group, Medtronic, Accell Group, Anika Therapeutics, Inc., B. Braun Melsungen AG, Cardinal Health, DeRoyal Industries, Hollister, Integra LifeSciences Corporation, Medline Industries, Inc., PAUL HARTMANN AG, Essity Aktiebolag, Avita Medical, Suwelack Skin and Health Care AG, Healthpoint, Fort Worth, Advanced BioHealing, Mallinckrodt, RenovaCare, among others. Do you know how new drug market launch will be impacting the Skin Burns market CAGR? Download sample report @ Skin Burns Clinical Trials and Therapeutic Assessment Skin Burns Report Key Insights 1. Skin Burns Patient Population 2. Skin Burns Market Size and Trends 3. Key Cross Competition in the Skin Burns Market 4. Skin Burns Market Dynamics (Key Drivers and Barriers) 5. Skin Burns Market Opportunities 6. Skin Burns Therapeutic Approaches 7. Skin Burns Pipeline Analysis 8. Skin Burns Current Treatment Practices/Algorithm 9. Impact of Emerging Therapies on the Skin Burns Market Table of Contents 1. Key Insights 2. Executive Summary 3. Skin Burns Competitive Intelligence Analysis 4. Skin Burns Market Overview at a Glance 5. Skin Burns Disease Background and Overview 6. Skin Burns Patient Journey 7. Skin Burns Epidemiology and Patient Population 8. Skin Burns Treatment Algorithm, Current Treatment, and Medical Practices 9. Skin Burns Unmet Needs 10. Key Endpoints of Skin Burns Treatment 11. Skin Burns Marketed Products 12. Skin Burns Emerging Therapies 13. Skin Burns Seven Major Market Analysis 14. Attribute Analysis 15. Skin Burns Market Outlook (7 major markets) 16. Skin Burns Access and Reimbursement Overview 17. KOL Views on the Skin Burns Market 18. Skin Burns Market Drivers 19. Skin Burns Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer About DelveInsight DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Yahoo
25-02-2025
- Health
- Yahoo
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
Findings in Burns Journal confirm NexoBrid's superiority over standard of care in pediatric patients with deep thermal burnsNexoBrid is approved for pediatric use in the U.S., E.U. and Japan YAVNE, Israel, Feb. 25, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of its Phase III Children Innovative Debridement Study (CIDS) in Burns, the peer-reviewed Journal of the International Society for Burn Injuries (ISBI). The study evaluated the efficacy and safety of NexoBrid® compared to the standard of care (SOC) in pediatric patients with deep partial- and full-thickness thermal burns. Read the full publication here. The publication, titled 'Open-Label RCT of the Efficacy and Safety of NexoBrid Compared to SOC in Children with Burns,' presents findings that supported the label expansion of NexoBrid for pediatric patients in the E.U. (2023) and U.S. (2024). These results reinforce NexoBrid's clinical benefits as a rapid, effective, and non-surgical alternative for eschar removal in pediatric burn patients, validating its significance as a transformative treatment in burn care. "Pediatric burn patients account for approximately 30% of all burn cases, and their treatment presents unique challenges. Surgical procedures can be particularly traumatic for young patients, making non-surgical alternatives essential" said Professor Jose Ramón Martínez-Méndez, Head of Burns Unit, University Hospital La Paz, Madrid, Spain. "NexoBrid provides a rapid, non-surgical solution that effectively removes eschar while preserving healthy tissue, addressing the critical need to protect viable dermis and improve outcomes for pediatric burn patients." About the CIDS Phase III The CIDS Phase III was a multicenter, multinational, randomized, controlled, open label study, conducted in pediatric patients with deep partial thickness (DPT) and full thickness (FT) thermal burns across 36 burn centers in the US, EU, Israel and India. The study randomized 145 pediatric patients, ranging from newborn to eighteen years of age, randomized 1:1 to receive either NexoBrid or SOC. Key Findings:All co-primary endpoints were successfully met: 1. Faster eschar removal: NexoBrid achieved complete eschar removal in a median time of one day compared to six days with SOC (p < 0.001) 2. Reduced wound area excised: The mean percentage of wound area surgically excised was significantly lower in the NexoBrid arm vs. SOC (1.5% vs. 48.1%, respectively, p < 0.001) 3. Comparable long-term outcomes: At 12 months, NexoBrid demonstrated comparable cosmesis and functional outcomes to SOC, with lower (better) MVSS scores of 3.8 in the NexoBrid arm vs. 4.9 in the SOC (test for non-inferiority, p < 0.001) Additional findings: 4. Reduced need for surgery: 8.3% of NexoBrid treated patients required surgical excision vs. 64.4% of patients treated with SOC (p < 0.001) 5. High efficacy: 94.2% of patients treated with NexoBrid achieved complete eschar removal 6. Comparable safety profile: NexoBrid demonstrated comparable safety profile to SOC About NexoBrid NexoBrid® is a topically administered biological orphan drug that enzymatically removes eschar while preserving viable tissue in patients with deep partial- and full-thickness thermal burns. It is approved for use in in more than 40 countries, including the United States, European Union, and Japan. NexoBrid development has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract HHSO100201500035C. This contract provided funding and technical support for the pivotal U.S. Phase 3 clinical study (DETECT), the randomized, controlled pivotal clinical trial for use in the pediatric population (CIDS), the marketing approval registration process for NexoBrid as well as its procurement and availability under the expanded access treatment protocol (NEXT). Additional projects for evaluation of NexoBrid funded under the BARDA contract include establishment of a pre-emergency use data package and development of the health economic model to evaluate the cost savings impact to enable market adoption in the United States. About MediWound MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of innovative biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries. MediWound's first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Leveraging its proprietary enzymatic technology, MediWound is advancing EscharEx®, a promising candidate currently in Phase III development for the debridement of chronic wounds. Phase II clinical trials have shown EscharEx has distinct advantages over the currently available $375+ million drug for wound debridement, presenting a unique opportunity for significant market growth. For more information visit and follow us on LinkedIn. Cautionary Note Regarding Forward-Looking Statements MediWound cautions you that all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect, believe, or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties, and factors, all of which are difficult to predict and many of which are beyond our control. Actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as 'anticipates,' 'intends,' 'estimates,' 'plans,' 'expects,' 'continues,' 'believe,' 'guidance,' 'outlook,' 'target,' 'future,' 'potential,' 'goals' and similar words or phrases, or future or conditional verbs such as 'will,' 'would,' 'should,' 'could,' 'may,' or similar expressions. Specifically, this press release contains forward-looking statements concerning the anticipated progress, development, study design, expected data timing, objectives anticipated timelines, expectations and commercial potential of NexoBrid and EscharEx®. Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties associated with the uncertain, lengthy and expensive nature of the product development process; the timing and conduct of our studies of EscharEx, including the timing, progress and results of current and future clinical studies, and our research and development programs; the approval of regulatory submission by the FDA, the European Medicines Agency or by any other regulatory authority, our ability to obtain marketing approval of EscharEx in the U.S. or other markets; the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of our products and products; our expectations regarding future growth, including our ability to develop new products; market acceptance of NexoBrid and EscharEx; our ability to maintain adequate protection of our intellectual property; competition risks; the need for additional financing; the impact of government laws and regulations and the impact of the current global macroeconomic climate on our ability to source supplies for our operations or our ability or capacity to manufacture, sell and support the use of our products and product candidates in the future. These and other significant factors are discussed in greater detail in MediWound's annual report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission ('SEC') on March 21, 2024 and Quarterly Reports on Form 6-K and other filings with the SEC from time-to-time. These forward-looking statements reflect MediWound's current views as of the date hereof and MediWound undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law. MediWound Contacts: Hani LuxenburgChief Financial OfficerMediWound Daniel FerryManaging DirectorLifeSci Advisors, LLCdaniel@ Media Contact: Ellie HansonFINN Partners for Sign in to access your portfolio
